Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Pierre Mach

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Journal for Immunotherapy of Cancer|November 27, 2014
iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccineStéphanie Corgnac, Rachel Perret, Lianjun Zhang, et al.
Cancer Immunity|August 15, 2003
In vivo targeting of an anti-tumor antibody coupled to antigenic MHC class I complexes induces specific growth inhibition and regression of established syngeneic tumor graftsAlena Donda, Valérie Cesson, Jean-Pierre Mach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2006
Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugatesValérie Cesson, Kathrin Stirnemann, Bruno Robert, et al.
European Journal of Biochemistry|June 6, 2002
Substrate specificity of human kallikrein 2 (hK2) as determined by phage display technologySylvain M Cloutier, Jair Ribeiro Chagas, Jean-Pierre Mach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
MHC class I-related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cellsClaire Germain, Christel Larbouret, Valérie Cesson, et al.
Protein Engineering, Design & Selection : PEDS|September 16, 2008
Redirecting NK cells mediated tumor cell lysis by a new recombinant bifunctional proteinClaire Germain, Emmanuelle Campigna, Imed Salhi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 13, 2014
Mammalian target of rapamycin complex 1 orchestrates invariant NKT cell differentiation and effector functionLianjun Zhang, Benjamin O Tschumi, Stéphanie Corgnac, et al.
Medicinal Chemistry (Shariqah (United Arab Emirates))|November 21, 2009
An infrared reflection-absorption spectroscopic (IRRAS) study of the interaction of lipid A and lipopolysaccharide Re with endotoxin-binding proteinsAndreas Kerth, Patrick Garidel, Jörg Howe, et al.
Neoplasia (New York, N.Y.)|March 21, 2012
In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruptionChristel Larbouret, Nadège Gaborit, Thierry Chardès, et al.
Cancer Immunology, Immunotherapy : CII|December 18, 2012
CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responsesStéphanie Corgnac, Rachel Perret, Laurent Derré, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Journal for Immunotherapy of Cancer|November 27, 2014
iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccineStéphanie Corgnac, Rachel Perret, Lianjun Zhang, et al.
Cancer Immunity|August 15, 2003
In vivo targeting of an anti-tumor antibody coupled to antigenic MHC class I complexes induces specific growth inhibition and regression of established syngeneic tumor graftsAlena Donda, Valérie Cesson, Jean-Pierre Mach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2006
Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugatesValérie Cesson, Kathrin Stirnemann, Bruno Robert, et al.
European Journal of Biochemistry|June 6, 2002
Substrate specificity of human kallikrein 2 (hK2) as determined by phage display technologySylvain M Cloutier, Jair Ribeiro Chagas, Jean-Pierre Mach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2005
MHC class I-related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cellsClaire Germain, Christel Larbouret, Valérie Cesson, et al.
Protein Engineering, Design & Selection : PEDS|September 16, 2008
Redirecting NK cells mediated tumor cell lysis by a new recombinant bifunctional proteinClaire Germain, Emmanuelle Campigna, Imed Salhi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 13, 2014
Mammalian target of rapamycin complex 1 orchestrates invariant NKT cell differentiation and effector functionLianjun Zhang, Benjamin O Tschumi, Stéphanie Corgnac, et al.
Medicinal Chemistry (Shariqah (United Arab Emirates))|November 21, 2009
An infrared reflection-absorption spectroscopic (IRRAS) study of the interaction of lipid A and lipopolysaccharide Re with endotoxin-binding proteinsAndreas Kerth, Patrick Garidel, Jörg Howe, et al.
Neoplasia (New York, N.Y.)|March 21, 2012
In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruptionChristel Larbouret, Nadège Gaborit, Thierry Chardès, et al.
Cancer Immunology, Immunotherapy : CII|December 18, 2012
CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responsesStéphanie Corgnac, Rachel Perret, Laurent Derré, et al.
Pageof 3